Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

Inhaled corticosteroids (ICS), short- and long-acting β 2-agonists (SABA and LABA), long-acting muscarinic antagonists (LAMA) and fixed-dose combinations of LABA and ICS are the cornerstones of ...

The combination of an inhaled corticosteroid, long-acting muscarinic antagonist, and a long-acting beta2 adrenergic agonist is important to GSK as it must replace lost sales from its ageing ...

Key life-cycle management strategies for the future include combining drugs from different classes, of which the LABA/LAMA (long-acting muscarinic agonist) combinations are set to be the greatest ...

Umeclidinium is a long-acting muscarinic antagonist ... The pharmacologic effects of beta2-adrenergic agonist drugs, including vilanterol, are at least in part attributable to stimulation of ...

Enerzair (formerly QVM149) consists of long-acting beta agonist (LABA) indacaterol, long-acting muscarinic antagonist (LAMA) glycopyrronium, and inhaled corticosteroid (ICS) mometasone furoate ...

Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist ... combining a long-acting muscarinic antagonist, umeclidinium ...

Muscarinic (M) receptors involved in the ... If the equivalence of tiotropium with long-acting β2-agonists will be demonstrated in terms of efficacy, at least in some asthma phenotypes ...

Trelegy Ellipta, a triple-therapy inhaler containing an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA), was found to offer ...